Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$9.72

0.2 (2.10%)

, CELG

Celgene

$87.67

2.75 (3.24%)

10:50
01/07/19
01/07
10:50
01/07/19
10:50

Alliance for Regenerative Medicine (ARM) to hold a briefing

2019 Cell & Gene Therapies State of the Industry Briefing will be held in San Francisco on January 7 with webcasted company presentations to begin at 11 am; not all company presentations may be webcasted. Webcast Link

IOVA

Iovance Biotherapeutics

$9.72

0.2 (2.10%)

CELG

Celgene

$87.67

2.75 (3.24%)

AUTL

Autolus Therapeutics

$34.44

-0.17 (-0.49%)

BLUE

Bluebird Bio

$114.17

7.67 (7.20%)

ONCE

Spark Therapeutics

$44.26

3.09 (7.51%)

BOLD

Audentes Therapeutics

$24.66

1.61 (6.98%)

FIXX

Homology Medicines

$24.93

0.46 (1.88%)

  • 07

    Jan

  • 07

    Jan

  • 07

    Jan

  • 28

    Jan

  • 18

    May

  • 28

    May

IOVA Iovance Biotherapeutics
$9.72

0.2 (2.10%)

12/31/18
RILY
12/31/18
INITIATION
Target $24
RILY
Buy
Iovance Biotherapeutics resumed with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico resumed coverage of Iovance Biotherapeutics and kept his firm's Buy rating and $24 price target on the shares.
11/12/18
RILY
11/12/18
NO CHANGE
Target $24
RILY
Buy
Iovance lifileucel data support melanoma optimism, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Iovance Biotherapeutics with a $24 price target after the company presented Phase II lifileucel melanoma data this weekend. The analyst views the 30% confirmed overall response rate and early duration of response as "impressive" for the highly refractory post-PD-1 patients studied. The analyst says these results validate his optimism for the potentially registrational cohort 4 of lifileucel in melanoma, guided to start in early 2019.
11/06/18
WELS
11/06/18
NO CHANGE
WELS
Outperform
Iovance data supportive of potential approval, says Wells Fargo
The 38% response rate and duration greater than six months seen in this morning's abstract data for tumor-infiltrating lymphocyte therapeutic lifleucel in PD1 experienced metastatic melanoma are "highly differentiated from other cell therapies in solid tumors and supportive of potential approval if confirmed by pivotal study," Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst keeps an Outperform rating on shares of Iovance Biotherapeutics. The stock in morning trading is down 10%, or 99c, to $8.46.
10/12/18
HCWC
10/12/18
NO CHANGE
HCWC
Iovance Biotherapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics and raised his price target on shares to $26 from $22, following the outcome of the end-of-Phase 2 meeting with the FDA regarding lead candidate LN-144. Pantginis called the interactions with the FDA "successful," and believes that Iovance will "further pursue its discussion with the agency in order to find the best path forward for LN-144 followed by assets across multiple indications." Additionally, the analyst reiterated his belief that Iovance is a compelling takeout candidate, and added that the company's cash resources provide strong leverage in any discussions.
CELG Celgene
$87.67

2.75 (3.24%)

01/04/19
01/04/19
DOWNGRADE

Outperform
BeiGene downgraded to Outperform at CLSA as Celgene goes 'from friend to foe'
As previously reported, CLSA analyst David Li downgraded BeiGene to Outperform from Buy following the news yesterday of Bristol-Myers' (BMY) proposed acquisition of Celgene (CELG) in a note titled "From friend to foe." He thinks Celgene is unlikely to continue to cooperate with BeiGene on its PD-1 after the deal goes through and also worries about the three commercialized products licensed from Celgene and about the company selling out of its BeiGene stake, he tells investors. He lowered his price target on BeiGene shares to HK$89.86 from HK$121.34.
01/04/19
BARD
01/04/19
UPGRADE
Target $92
BARD
Outperform
Baird upgrades Celgene to Outperform, says deal discount looks high
As reported previously, Baird analyst Brian Skorney upgraded Celgene (CELG) to Outperform from Neutral. The analyst believes the current price discount to the Bristol-Myers (BMY) deal price does not makes sense based on the probability of the deal closing in the high $90's. He attributes a 35-40% probability of the deal falling through, but he is more bullish on the deal as management is now shown to be willing sellers. Skorney has a $92 price target on Celgene shares, which are up about 2% in pre-market trading to $82 per share.
01/04/19
WELS
01/04/19
NO CHANGE
Target $84
WELS
Market Perform
Celgene price target cut to $84 from $90 at Wells Fargo
Wells Fargo analyst Jim Birchenough maintained a Market Perform rating on Celgene (CELG) but cut his price target to $84 following yesterday's proposed acquisition by Bristol-Myers (BMY). In a research note to investors, Birchenough says he continues to see fundamental risk to both Celgene value and deal closing with poor visibility on long-term growth for the combined company and risk to ongoing Revlimid patent litigation. With the debate on Revlimid generic timing and impact likely to remain on overhang, the analyst believes that the proposed acquisition gives greater leverage to generics, reduces the likelihood of a reasonable settlement and complicates any settlement process.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
AUTL Autolus Therapeutics
$34.44

-0.17 (-0.49%)

11/29/18
WELS
11/29/18
NO CHANGE
Target $50
WELS
Outperform
Autolus Therapeutics price target raised to $50 from $38 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Autolus Therapeutics to $50 from $38 after the company filed its annual report on Form 20-F for the fiscal year ended September 2018. The analyst reiterates an Outperform rating on the shares.
10/24/18
HCWC
10/24/18
INITIATION
Target $45
HCWC
Buy
Autolus Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Autolus Therapeutics (AUTL) with a Buy rating and $45 price target. The stock is currently trading at a market capitalization of about $1.2B, which is a "significant discount" to the $2.7B market capitalization that the Street is valuing peer Allogene's (ALLO) "limited pipeline," Chattopadhyay tells investors in a research note. With a "slew of data releases between" ASH 2018 and ASH 2019, the analyst expects a :potential convergence in valuation."
07/27/18
07/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) reinstated with a Neutral at BofA/Merrill. 2. uniQure (QURE) initiated with an Overweight at Cantor Fitzgerald. 3. Autolus Therapeutics (AUTL) initiated with a Neutral at Goldman Sachs. 4. Pure Storage (PSTG) initiated with an Overweight at JPMorgan. 5. Plains All American (PAA) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/18
GSCO
07/26/18
INITIATION
GSCO
Neutral
Autolus Therapeutics initiated with a Neutral at Goldman Sachs
BLUE Bluebird Bio
$114.17

7.67 (7.20%)

12/19/18
RAJA
12/19/18
INITIATION
Target $165
RAJA
Strong Buy
Bluebird Bio initiated with a Strong Buy at Raymond James
Raymond James initiated Bluebird Bio with a Strong Buy and $165 price target.
12/03/18
ADAM
12/03/18
NO CHANGE
ADAM
Canaccord has positive expectations for Bluebird after bb 21217 data released
Canaccord analyst John Newman maintained a Buy rating and $250 price target on Bluebird Bio, after the company recently released bb 21217 data. Newman has continued positive expectations for the active programs, and for bb2121's clinical progression. He added that "given the previous bb2121 dose response data, we continue to expect strong response data from the ongoing Phase 2 KarMMa trial, the ongoing Phase 1 CRB-401 trial in RRMM, and future Phase 3 trial." The analyst also noted that Bluebird reported cash and marketable securities of ~$2B, which he believes should be able to fund the company to profitability.
12/06/18
12/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/18
PIPR
12/06/18
DOWNGRADE
Target $120
PIPR
Neutral
Bluebird Bio downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren downgraded Bluebird Bio to Neutral and cut his price target for the shares to $120 from $240. The stock closed Tuesday down $2.85 to $113.65. The company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks," Van Buren tells investors in a research note. And while these are risks worth taking for octorefractory multiple myeloma patients with just days to live, the proposition for beta thalassemia and sickle cell patients "is much more difficult," says the analyst. Further, Van Buren believes that as LentiGlobin launches next year, the "exuberance and hope" of clinical development will soon transition to "high expectations for commercial performance." Key opinion leaders agree that broad uptake of LentiGlobin will be challenging, admits the analyst. He lowered his estimates for LentiGlobin and downgraded Bluebird Bio to Neutral.
ONCE Spark Therapeutics
$44.26

3.09 (7.51%)

11/16/18
11/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst James Faucette saying he thinks consensus estimates now imply a more realistic scenario for QCT margins and that lowered expectations on a resolution with Apple (AAPL) gives room for the stock to react positively should legal proceedings trigger a settlement. 2. Spark Therapeutics (ONCE) upgraded to Neutral from Underperform at Credit Suisse with analyst Martin Auster saying with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic. 3. Armstrong Flooring (AFI) upgraded to Buy from Hold at Gabelli with analsyt Alvaro Lacayo saying the sale of the wood business is a transformative deal and removes two underperforming segments that have been under increased pressure from private label competition. 4. DSW (DSW) upgraded to Neutral from Negative at Susquehanna. 5. PG&E (PCG) and Edison International (EIX) were upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/18
FBCO
11/16/18
UPGRADE
Target $44
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Martin Auster upgraded Spark Therapeutics (ONCE) to Neutral from Underperform but lowered his price target to $44 from $48. In a research note to investors, Auster says that with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic.However, Auster says Spark has been under significant pressure since providing an update on its hemophilia A, and believes most of the value for that program has already been discounted in the share price. Though there is limited visibility in the near-term, he sees optionality going forward within the Pompe program and/or a possible reemergence of the hem A platform ~mid-2019 from either an improved profile for SPK-8011 with prophy steroids or encouraging early data from Spark's second compound SPK-8016.
11/16/18
FBCO
11/16/18
UPGRADE
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
11/15/18
HCWC
11/15/18
NO CHANGE
Target $48
HCWC
Buy
uniQure's AMT-061 'living up to high expectations,' says H.C. Wainwright
uniQure (QURE) has provided investors with "a compelling glimpse at what the future hold for Hemophilia B patients" after issuing an update on its AMT-061 dose confirmation study, according to H.C. Wainwright analyst Debjit Chattopadhyay. The mean Factor IX activity at six weeks was 31%, which is on par with Spark Therapeutics' (ONCE) SPK-9001, said Chattopadhyay. The analyst, who thinks AMT-061 is "living up to high expectations" and views it being positioned as "not only the best-in-class one-and-done solution, but also, the first to market," keeps a Buy rating and $48 price target on uniQure shares.
BOLD Audentes Therapeutics
$24.66

1.61 (6.98%)

11/26/18
JPMS
11/26/18
INITIATION
Target $35
JPMS
Overweight
Audentes Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Audentes Therapeutics with an Overweight rating and $35 price target. The stock has pulled 40% since early October, which represents an attractive long-term entry point, Rama tells investors in a research note. He believes the "de-risked nature" of the known clinical data for gene therapy lead assets AT132 in X-Linked Myotubular Myopathy and AT342 in Crigler-Najjar Syndrome "goes underappreciated" at current share levels.
10/12/18
HCWC
10/12/18
NO CHANGE
Target $33
HCWC
Buy
Audentes Therapeutics price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Audentes Therapeutics to $33 after the company closed another secondary offering at $29 per share, which he notes represents a 17% discount to the January offering, which diluted shareholders by about 14%. The latest offering "leaves more than a sour taste in our mouths," Chattopadhyay tells investors in a research note. He believes Audentes had "no dire need to access the capital markets" and finds the timing and pricing of the offering "to be a little suspect." However, Chattopadhyay keeps a Buy rating on Audentes Therapeutics.
11/07/18
WBLR
11/07/18
DOWNGRADE
WBLR
Market Perform
Audentes downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded Audentes Therapeutics to Market Perform following the company's Q3 results. The analyst says increased competition in Pompe disease is giving him pause.
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FIXX Homology Medicines
$24.93

0.46 (1.88%)

01/07/19
01/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Pivotal Research. 2. Dell Technologies (DELL) initiated with a Buy at Goldman Sachs. 3. Tencent Music (TME) initiated with an Overweight at KeyBanc, a Buy at Goldman Sachs, and a Hold at Stifel. 4. Huntington Ingalls (HII) initiated with a Neutral at JPMorgan. 5. Homology Medicines (FIXX) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
ADAM
01/07/19
INITIATION
Target $37
ADAM
Buy
Homology Medicines initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Homology Medicines with a Buy rating as she views its gene editing platform tool as the most promising for in vivo therapy, overcoming the challenges with safety and efficacy that have limited nuclease-based editing platforms. The analyst expects its KU gene-transfer program updates to be a primary value driver in 2019. Gilson has a $37 price target on Homology Medicines shares.
09/07/18
RILY
09/07/18
INITIATION
Target $18.5
RILY
Neutral
Homology Medicines initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Homology Medicines with a Neutral rating and $18.50 price target.
04/24/18
BTIG
04/24/18
INITIATION
Target $35
BTIG
Buy
Homology Medicines initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Homology Medicines with a Buy rating and a price target of $35, saying the company is "in the process of rapidly advancing a more effective and more efficient, next-generation technology" within the gene therapy/gene editing landscape. Hazlett points to the company's "recent discovery of hematopoietic stem cell-derived adeno-associated virus vector which possess a cluster of important differentiating characteristics that appear highly amenable to both gene therapy and gene editing", concluding that Homology Medicines operations would be attractive to a potential suitor.

TODAY'S FREE FLY STORIES

FMBH

First Mid-Illinois Bancshares

$33.31

-0.13 (-0.39%)

08:35
01/24/19
01/24
08:35
01/24/19
08:35
Earnings
First Mid-Illinois Bancshares reports Q4 EPS 62c, consensus 73c »

Reports Q4 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:35
01/24/19
01/24
08:35
01/24/19
08:35
General news
U.S. initial jobless claims dropped 13k to 199k in the week ended January 19 »

U.S. initial jobless…

CTRA

Contura Energy

$64.21

-0.64 (-0.99%)

08:34
01/24/19
01/24
08:34
01/24/19
08:34
Hot Stocks
Contura Energy sees total 2019 coal shipments of 24.6M-26.7M tons »

Contura Energy expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 31

    Jan

08:34
01/24/19
01/24
08:34
01/24/19
08:34
Conference/Events
U.S. Energy Association to hold a forum »

15th Annual State of the…

SPA

Sparton

$18.40

0.08 (0.44%)

08:34
01/24/19
01/24
08:34
01/24/19
08:34
Hot Stocks
Sparton announces expiration of HSR waiting period with respect to acquisition »

Sparton Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POL

PolyOne

$31.07

-0.17 (-0.54%)

08:33
01/24/19
01/24
08:33
01/24/19
08:33
Recommendations
PolyOne analyst commentary  »

PolyOne elevated to Fresh…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

08:32
01/24/19
01/24
08:32
01/24/19
08:32
General news
Jobless Claims data reported »

Week of 1/19 Jobless…

GOOS

Canada Goose

$49.59

-0.4 (-0.80%)

, GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

08:29
01/24/19
01/24
08:29
01/24/19
08:29
Downgrade
Canada Goose, Alphabet Class A, Alphabet, Facebook rating change  »

Canada Goose downgraded…

GOOS

Canada Goose

$49.59

-0.4 (-0.80%)

GOOGL

Alphabet Class A

$1,085.27

6.59 (0.61%)

GOOG

Alphabet

$1,076.04

5.32 (0.50%)

FB

Facebook

$144.35

-3.45 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

SO

Southern Company

$47.58

0.47 (1.00%)

08:28
01/24/19
01/24
08:28
01/24/19
08:28
Upgrade
Southern Company rating change  »

Citi upgrades Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$80.52

-0.23 (-0.28%)

, ADDYY

Adidas

$0.00

(0.00%)

08:27
01/24/19
01/24
08:27
01/24/19
08:27
Recommendations
Nike, Adidas analyst commentary  »

Nike likely to gain most…

NKE

Nike

$80.52

-0.23 (-0.28%)

ADDYY

Adidas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

$0.92

-0.0193 (-2.05%)

08:27
01/24/19
01/24
08:27
01/24/19
08:27
Initiation
BioTime initiated  »

BioTime initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:27
01/24/19
01/24
08:27
01/24/19
08:27
Conference/Events
The Washington Association of Money Managers holds a panel discussion »

The WAMM holds a panel…

INCY

Incyte

$75.20

-2.11 (-2.73%)

08:25
01/24/19
01/24
08:25
01/24/19
08:25
Upgrade
Incyte rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 24

    Feb

BLPH

Bellerophon

$0.68

-0.2007 (-22.79%)

08:24
01/24/19
01/24
08:24
01/24/19
08:24
Initiation
Bellerophon initiated  »

Bellerophon initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AAWW

Atlas Air

$49.61

-0.5 (-1.00%)

08:22
01/24/19
01/24
08:22
01/24/19
08:22
Conference/Events
The Wings Club to hold a luncheon meeting »

President & CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CP

Canadian Pacific

$195.71

0.02 (0.01%)

08:21
01/24/19
01/24
08:21
01/24/19
08:21
Recommendations
Canadian Pacific analyst commentary  »

Canadian Pacific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

08:21
01/24/19
01/24
08:21
01/24/19
08:21
Conference/Events
European Central Bank President Draghi to hold press conference »

ECB President Draghi…

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$174.98

-1.01 (-0.57%)

08:20
01/24/19
01/24
08:20
01/24/19
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$64.45

0.22 (0.34%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$61.79

-0.6 (-0.96%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$105.40

0.16 (0.15%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.42

-0.34 (-0.64%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.